Novel Lung Cancer Vaccine Shows Promise In Fighting Early-Stage Lung Cancer

An experimental vaccine that triggers the patient’s immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer. Thoracic surgeons at Rush University Medical Center are researching the vaccine called MAGE-A3 Antigen-Specific Cancer Immunotherapeutic, which is designed to kill cancer cells without harming normal cells. Rush is one of only five hospitals in Illinois offering the vaccine.

More: continued here

Filed under: Immune System / Vaccines on April 10th, 2009